Anthill Technologies Announces Agreement with Zafgen
News Aug 26, 2008
Zafgen, Inc. is a Boston-based biopharmaceutical company which develops obesity therapy based on the vascular targeting of adipose tissue.
Under the agreement, Anthill will use its ACOS™ high-speed synthesis and on-demand purification capabilities to assist Zafgen in the development of lead compounds for its obesity therapy programs.
"We are very pleased to have the opportunity to assist Zafgen in its efforts to find novel and effective therapies to combat obesity," said Dr. Joseph C. Hogan Jr., CEO of Anthill Technologies. "We fully expect that our high-speed chemistry expertise and unique capabilities will help Zafgen to accelerate its obesity therapy discovery program."
Global Experts Meeting on Frontiers in Biosimilars and Biologics Congress
Oct 24 - Oct 26, 2019